Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza B Hemagglutinin Protein (Victoria Lineage Subtype) (HA)
- Target
- HA
- Molecular classification
- Glycoprotein, Viral protein, Hemagglutinin
01
Overview
The hemagglutinin (HA) protein of Influenza B virus, specifically from the Victoria lineage, is a major surface glycoprotein and a critical antigenic determinant. It plays essential roles in viral entry into host cells and is the primary target for neutralizing antibodies. The Victoria lineage is one of two main evolutionary branches of Influenza B viruses. HA is a trimeric glycoprotein responsible for receptor binding to sialic acids on host cells and mediating membrane fusion. Due to antigenic differences between Victoria and Yamagata lineages, effective vaccines must contain representatives from both. HA deletion variants and other mutations can impact immune escape and vaccine effectiveness.
- Other names
- B/Victoria/2/1987-like hemagglutininVictoria lineage HAInfluenza B HA (Victoria)
02
Mechanism of action
Neutralization of viral entry via antibody binding to HA, preventing receptor binding or membrane fusion.
03
Biological functions
Receptor bindingMembrane fusionViral entryAntigen presentationImmune response
04
Disease associations
InfectionInfluenza
05
Safety considerations
Antigenic drift leading to vaccine escapePotential for deletion variants to alter immune responseLineage mismatch in vaccine composition
06
Interacting drugs
NA (Neutralizing antibodies - vaccine induced)
07
Biomarkers
Antibody titers against Victoria lineage HAHA sequence variants for vaccine effectiveness monitoring
Beyond the preview
Go deeper on Influenza B Hemagglutinin Protein (Victoria Lineage Subtype) (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza B Hemagglutinin Protein (Victoria Lineage Subtype) (HA).